Pandemic Paradox: New Flu Virus Keeps Researchers and Health Officials Guessing  by Shekhar, Chandra
Chemistry & Biology
InnovationsPandemic Paradox: New Flu Virus Keeps Researchers
and Health Officials Guessing
Chandra Shekhar
DOI 10.1016/j.chembiol.2009.07.002When avian flu jumped the species barrier
to claim human victims in the late 1990s,
scientists warned that it could evolve
further and trigger a pandemic. And now,
a decade later, a pandemic has indeed
struck—but from an entirely different and
unexpected source. Carrying a mishmash
of genetic parts from human, avian, and
swine influenza viruses, the newpathogen
appears to have crossed over to us from
pigs, not birds. In a matter of weeks, it
has spread to practically every region on
the globe, claiming an estimated one
million infections in the United States
alone and triggering an unprecedented
global effort to track and ascertain its
behavior. Despite its spectacular prog-
ress, however, this swine flu pandemic
has so far caused only a few hundred
cases of severe illness or death, and
its potential long-term impact remains
unclear. ‘‘As of now, neither from point of
view of spread nor virulence can the virus
be considered severe,’’ says virologist
William Gallaher, PhD, of Louisiana State
University in New Orleans. ‘‘But all bets
are off as to what will happen when the
classic flu season begins in the northern
hemisphere where most people live. If
the virus gets cracking, 25% attack rates
are not out of the realm of possibility.’’
The current outbreak has ominous simi-
larities to ‘‘the mother of all pandemics,’’
the 1918 Spanish Flu virus that infected
nearly a third of the world population and
killed approximately 100 million people.
Then, as now, the infectious agent was
an influenza A virus of the H1N1 subtype.
Then, as now, a mild but widespread
wave of infection struck the northern
hemisphere in summer, well before the
normal flu season. (The devastating wave
that followed in the fall of 1918 did most
of the damage). Then, as now, the elderly
were spared and young adults dispropor-
tionately affected; the opposite of what
happens with routine seasonal flu. ‘‘I
don’t want to cry wolf, but whenever you
see a pattern like that, you’ve got to keep
your eyes peeled,’’ says epidemiologist
LoneSimonsen, PhD, ofGeorgeWashing-
ton University.
A key feature of influenza A pandemics
is ‘‘antigenic shift’’: the appearance of
a virus with such a significantly different
set of surface proteins that most people
have no immunity to the infection. From
an immune standpoint, the two key viral
proteins are hemagglutinin, which comes
in 16 varieties (H1–H16), and neuramini-
dase, which comes in nine (N1–N9). The
agents of the three major pandemics of
the last century—in 1918, 1957, and
1968—each sported such an ‘‘antigenic
shift’’ in their surface proteins. In each
case, as the population developed ‘‘herd’’
immunity, the viruses evolved under
selective pressure into seasonal strains
or disappeared altogether. (Currently,
seasonal flu is mostly caused by the
H1N1, H3N2, or influenza B subtypes.
The H2N2 subtype that caused the 1957
pandemic has not been detected in
humans since 1968.) How does the 2009
swine flu strain rate on the antigenic
scale? Sequence data indicate that its
hemagglutinin and neuraminidase differ
by about 27% and 18% in amino acid
sequence from the corresponding pro-
teins in the seasonal H1N1 strain. ‘‘That
amounts to a major antigenic shift,’’ says
Gallaher.
Some researchers such as Peter Pal-
ese, PhD, a microbiologist at the Mount
Sinai School of Medicine in New York,
feel that the change is not significant
enough to qualify as antigenic shift, but
is instead a case of antigenic ‘‘drift.’’ Pal-
ese points out that the novel virus is still
part of the H1N1 subtype, whereas prior
pandemics were caused by entirely new
subtypes, such as the H3N2 virus that
caused the 1968 pandemic. ‘‘In the old
days, we wouldn’t have called this a
pandemic,’’ he says.
Some clues lie in the novel virus’s
intriguing lineage. Central to the influenza
A virus’s success as a pandemic agent is
its unique ability to swap one or more of
its eight genome segments with other
viruses of this family to continually rein-
vent itself. Thus, a pair of genetically
distinct viruses could recombine in as
many as 256 different ways; one of these
new versions may have just the right
genetic mix to evade the human immune
system and/or cause severe disease.
The 2009 swine flu virus is a so-called
triple reassortant, carrying a novel mix of
one human, two avian, and five swine
flu gene segments. Its hemagglutinin
and neuraminidase proteins seem well
adapted for human infection, studies
show. But other features of the pathogen
suggest lower virulence. Compared to
the viruses involved in the 1957 and
1968 pandemics, the novel pathogen
has several more genes from nonhuman
flu strains. This may make it less adapted
for human disease. Further, it lacks a
virulence factor present in all prior
pandemics: PB1-F2, a small viral protein
that makes patients sicker andmore likely
to catch bacterial pneumonia. These
factors may explain why the virus has so
far caused mostly mild disease, with a
case fatality rate comparable to seasonal
flu. ‘‘Iwould argue that it is actually a fourth
seasonal influenza strain,’’ says Palese.
‘‘But if you insist on calling it a pandemic
strain, it’s a very mild one.’’
The virus could of course turn nastier
with further mutation or reassortment; for
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sequence for PB1-F2 from another flu
virus infecting the same patient. ‘‘Only
a few tweaks and changes separate
a mild virus from a virulent one,’’ says
Gallaher. ‘‘A single case of mixed
infection could help the virus become
‘humanized’ and pose a much greater
threat.’’ However, as Palese points out,
a virus that turns more virulent in one
aspect may become less effective in
other aspects. Avian flu, for instance, is
extremely virulent both in humans and
chickens, but doesn’t transmit easily
between humans; if it does manage to
acquire this ability, it could lose some of
its virulence in the process. Likewise, if
the current swine flu virus turns more
deadly, it could end up being less infec-
tious. The worst-case scenario of a virus
that is both deadly and highly transmis-
sible, as was seen in 1918, ‘‘is a once
in a millennium event,’’ says Palese. In
any case, the 2009 swine flu virus appears
to be evolving very slowly. ‘‘It is breeding
extraordinarily true,’’ says Gallaher. ‘‘It’s
gone through tens of thousands of
people with virtually zero movement
genetically.’’
This could change, but if it does, it is
unlikely to catch scientists and health
authorities off guard. Influenza experts
the world over have come together in an
unprecedented effort to study the virus
and monitor its progress, aided by recent
boosts in research funding in response to
bird flu, anthrax, and other threats. As
a result, the novel swine flu virus is being
tracked virtually in real time, as attested
by the hundreds of sequences already
uploaded into the GenBank database.
‘‘We’ve never watched any agent of
human disease at the molecular level as
intensely as this one,’’ says Gallaher. ‘‘If
it changes at all, we should be able to688 Chemistry & Biology 16, July 31, 2009 ªpick it up quickly and correlate it with
changes in virulence.’’
This intense scrutiny is already paying
off. So far, the good news has been that
the common flu drugs oseltamivir (Tami-
flu) and zanamivir (Relenza) seem effec-
tive in fighting the novel virus. However,
Gallaher notes that three independent
H1N1 isolates from Hong Kong, Japan,
and Denmark found during the past few
days have a mutation in the neuramini-
dase protein, a change at position 274
from histidine to tyrosine, that makes the
virus resistant to Tamiflu. ‘‘If Tamiflu resis-
tance becomes widespread, it will take
away one of the weapons we have,’’
says Gallaher.
Another instance relates to the PB2
protein, which plays a key role in viral repli-
cation. The current virus has an avian
version of this protein and as a result is
better adapted to replicate in the warmer
bodies of birds (41C) than in humans. On
June 18th, a virus from Shanghai was re-
ported with a mutation in its PB2 protein
that would have helped it replicate at the
cooler temperature (33C) of the human
upper airway in winter—but fortunately
that sequence appears to have been erro-
neously reported (GenBank:ACS27790.2).
‘‘Even though this was a false alarm, it’s
really important to keep an eye on such
mutations,’’ says Princeton University
molecular biologist Richard A. Stein, MD,
PhD. ‘‘During the 1918 pandemic, when
the virus returned in the fall after an original
mild outbreak in the spring, the increased
mortality and morbidity were in part due
to this mutation.’’
Meanwhile, health officials are taking no
chances. On April 26th, just 11 days after
the first US case was identified, the US
government declared a public health
emergency of international concern. The
same day, WHO announced a phase 32009 Elsevier Ltd All rights reservedpandemic alert. On June 11th, the WHO
raised the pandemic alert to the highest
phase, 6, indicating sustained human-
human transmission caused by commu-
nity-level outbreaks in at least one country
in two or more WHO regions. While these
measures have placed health systems on
alert, their main effect as of now is
increased surveillance. The organization
does not recommend border closures or
travel restrictions and advises that
community-levelmeasures suchasschool
closings be considered on a case-by-case
basis. A universal vaccination campaign
would be the best weapon against the
current pandemic, but how feasible is it?
Such a campaign would need billions of
doses, but there are only about 35 major
vaccine manufacturers in the world. ‘‘It’s
a race to see how fast we can make the
vaccine,’’ says Robert Belshe, MD, who
directs the Center for Vaccine Develop-
ment at St. Louis University in Missouri.
Given the limited manufacturing capacity,
Belshe and others recommend giving
priority to vaccinating children and young
adults, who are falling sick at higher rates,
along with caregivers, essential workers,
and others with special needs.
Overall, the novel H1N1 virus is a mixed
bag—antigenically novel and infectious,
but relatively mild, susceptible to antiviral
drugs, andgenetically stable. Researchers
agree that its true nature will emerge this
fall when the regular flu season starts.
‘‘All eyes are on the southern hemisphere
epidemic right now,’’ says Simonsen.
‘‘The experience there will provide early
clues about whether the novel H1N1 virus
will evolve towards greater virulence and
whether it will replace or cocirculate with
the seasonal influenza viruses.’’
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